ARA-290: Side Effects & Safety
Part of the ARA-290 Complete Guide
Research Peptides
We may earn a commission if you purchase through this link, at no extra cost to you.
Overall Safety Profile
ARA-290 demonstrated a favorable safety profile in Phase 1 and Phase 2 clinical trials, with no serious drug-related adverse events. Crucially, it does not stimulate erythropoiesis — the primary safety concern with EPO-based therapeutics (blood thickening, thrombosis).
Reported Side Effects
- Injection site reactions: Mild and transient
- Headache: Occasionally reported
- No erythropoietic effects: No increase in red blood cells, hematocrit, or thrombosis risk
Important Limitations
Clinical data is limited to Phase 1/2 trials with relatively small patient numbers. Long-term safety beyond 28-day treatment courses has not been characterized. ARA-290 is not yet approved for any indication.
Potential Contraindications
- Known hypersensitivity to EPO-derived peptides
- Pregnancy and breastfeeding (no safety data)